Colorectal Cancer Drugs – Your New Guide to that Market, its R&D and Sales Potentials Do you want to assess the future of colorectal cancer medicines? Visiongain’s new report gives you revenue predictions for that industry from 2015, helping you stay ahead in knowledge and benefit your influence.
Our study shows you results, R&D trends, opportunities, interviews and revenue forecasts.
In that analysis you see predicted revenues to 2025 at overall world market, geographical and product level. You assess emerging trends, technologies and branded therapies. Explore the future of colorectal cancer drugs and their producers.
With our study, benefit your research, decisions, presentations and influence. Please read on now to discover how our new analysis can help your work.
Main ways Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025 helps you In these six main ways, Visiongain’s new analysis gives knowledge to make your work easier and faster, also benefiting your decisions and authority: • Revenue forecasting of the overall world market and 5 geographical submarkets – assess outlooks for development, production, marketing and sales, seeing what is possible • Nine leading drugs’ revenues to 2025 – find sales potentials for top brands, seeing how they can compete and succeed • Profiles of leading companies – assess participants’ results, portfolios, capabilities, deals and outlooks • R&D in colorectal cancer treatment – explore progress in research and development, finding technological, medical and commercial possibilities • Interviews with two other authorities – discover opinions to help you stay ahead in knowledge, finding what companies say and do • Analysis of what stimulates and restrains that pharma industry – assess challenges and opportunities, helping you gain advantages and succeed.
What forces stimulate the market for colorectal cancer treating medicines? In 2015 there exist at least 158 agents in clinical development for colorectal cancer. A large number of those products are in phase II development. Our report helps you understand opportunities in that field and how to use them.
As ageing populations increase, the incidence of cancer rises, leading to rising spending on cancer-treating medicines. That trend will continue. Are you ready for those commercial opportunities? Let our study guide you, showing what is possible.
Gain data found nowhere else, benefiting your influence on those anticancer medicines Visiongain’s study examines the colorectal cancer drugs market, using independent primary and secondary research. Gain discussions and data you find nowhere else.
In our new report you gain 35 charts, 29 tables and two research interviews to help you stay ahead in knowledge.
Forecasts for nine leading drugs – discover sales potentials Our new investigation gives you revenue forecasts to 2025 for nine leading products for treating colorectal cancer: • Avastin (Roche) • Erbitux (BMS/Merck Serono) • Xeloda (Roche) • Vectibix (Amgen) • Stivarga (Bayer) • Eloxatin (Sanofi) • TS-1 (Taiho Pharmaceuticals) • Zaltrap (Sanofi) • Cyramza (Eli Lilly)
In our work you also see profiles of leading companies and discussions of drugs in development. Our analysis explains activities and prospects of organisations developing, producing and marketing those therapies.
See what the future holds for products treating that disease. Our report explains, from 2015, pharma companies’ commercial prospects. Explore what the future holds.
Geographical markets – where lie the best sales and growth potentials? Our survey also shows forecasts to 2025 for these five regions, showing overall colorectal cancer drug revenues: • United States • European Union • Japan • APAC • Rest of the world.
That way you discover where revenue growth will occur in established pharma markets and in developing countries. Discover where the best prospects for sales and business expansion lie.
Get our independent study now – why wait and miss out? Our new report shows you trends, results, R&D and revenue forecasts. There you gain data and discussions to assess the future of treating colorectal cancer.
That investigation’s purpose is to benefit your knowledge and reputation for insight, increasing your chances of finding competitive advantages and succeeding.
Our study gives independent analysis, helping you stay ahead in competitive intelligence for cancer drug development, production and sales. Please get that report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the World Market for Colorectal Cancer Drugs 1.2 Why You Should Read This Report 1.3 How This Study Delivers 1.4 Main Questions Answered by this Analysis 1.5 Who is this Report For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQs) 1.8 Some Associated Reports 1.9 About Visiongain
2. Introduction to Colorectal Cancer and Treatments 2.1 Pathophysiology of Colorectal Cancer 2.2 Epidemiology of Colorectal Cancer 2.2.1 Incidence – Increases with Age 2.2.2 Mortality – Fourth-Leading Cause of Cancer Death 2.2.3 Survival – Depends on Stage of Cancer 2.3 Diagnosis – Benefits and Limitations 2.4 Treatment and Staging 2.4.1 Treatment Options 2.4.2 Staging in Colorectal Cancers 2.4.3 Treatment Depending on Stages
3. The World Colorectal Cancer Drugs Market, 2015-2025 3.1 Global Colorectal Cancer Drugs Market Forecast 2015-2025 3.2 Geographical Colorectal Cancer Drugs Market Forecasts 2015-2025 3.2.1 The US Colorectal Cancer Drugs Market, 2015-2025 3.2.1.1 The US Colorectal Cancer Drugs Market Forecast – Stagnant Growth 3.2.2 The Japanese Colorectal Cancer Drugs Market, 2015-2025 3.2.2.1 The Japanese Colorectal Cancer Drugs Market Forecast – High Price of Biosimilars Will Drive the Market 3.2.3 The EU Colorectal Cancer Drugs Market, 2015-2025 3.2.3.1 The EU Colorectal Cancer Drugs Market Forecast – Tough Regulatory Environment Will Slow Market Growth 3.2.4 The APAC Countries Colorectal Cancer Drugs Market, 2015-2025 3.2.4.1 The APAC Colorectal Cancer Drugs Market Forecast – Market Will Be Stimulated by Rising Incidence of Cancer Owing to Changes of Lifestyle 3.2.5 Rest of the World Colorectal Cancer Drugs Market, 2015-2025 3.2.5.1 Rest of the World Colorectal Cancer Drugs Market Forecast
4. The Top Colorectal Cancer Drugs: Revenue Forecasts, 2015-2025 4.1 Avastin (Roche) 4.1.1 Avastin Revenue Forecast – Leader of the Pack 4.1.2 Roche 4.2 Erbitux (BMS/Merck KGaA) 4.2.1 Erbitux Revenue Forecast – Will its Revenue be Eroded by Biosimilars? 4.2.2 BMS 4.2.3 Merck KGaA 4.3 Xeloda (Roche) 4.3.1 Xeloda Revenue Forecast – Declining Sharply 4.4 Vectibix (Amgen) 4.4.1 Vectibix Revenue Forecast – Sales Will Grow During the First Half of the Forecast Period 4.4.2 Amgen 4.5 Eloxatin (Sanofi) 4.5.1 Eloxatin Revenue Forecast – Declining Slowly 4.5.2 Sanofi 4.6 Zaltrap (Sanofi/Co-developed with Regeneron) 4.6.1 Zaltrap Revenue Forecast – Sales Expected to Grow Significantly Until 2020 4.7 Stivarga (Bayer) 4.7.1 Stivarga Revenue Forecast – Positive Growth Trend 4.7.2 Bayer 4.8 TS-1 (Taiho Pharmaceuticals) 4.8.1 TS-1 Revenue Forecast 4.8.2 Taiho Pharmaceuticals 4.9 Cyramza (Eli Lilly) 4.9.1 Cyramza Revenue Forecast – Additional Approval for mCRC Will Drive Sales 4.9.2 Eli Lilly
5. Emerging Therapies 5.1 Lonsurf (Taiho Pharmaceuticals) – Approved in Japan 5.2 Sym-004 (Symphogen) – Promising Results in Early Human Clinical Trials 5.3 IMMU-130/Labetuzumab-SN-38 (Immunomedics) – ADC with High Anti-Tumour Activity
6. R&D Pipelines for Colorectal Cancer Treatment 6.1 CPX-1 (Celator Pharmaceuticals) – Combination of Irinotecan HCl and Floxuridine 6.2 CT-011/Pidilizumab (CureTech) – Binds to PD-1 6.3 Dabrafenib/Tafinlar (GSK) – Inhibitor of B-Raf 6.4 E7820 (Eisai) – Inhibits Integrin Alpha 2 6.5 Entinostat (Syndax Pharmaceuticals) – Exhibits a Wide Range of Anti-Tumour Activity 6.6 Ganetespib (Synta Pharmaceuticals) – Inhibits Hsp90 6.7 LGX818/Encorafenib (Novartis) – Investigated in Several Trials 6.8 ABT-869/Linifanib (Abbott Laboratories) – Inhibits VEGF and PDGF Receptors 6.9 MORAb-004/Ontuxizumab (Morphotek, Inc.) – Targets Endosialin 6.10 Onartuzumab (Genentech) – Targets the Protein MET 6.11 JX-594 (SillaJen) – Oncolytic Virus 6.12 PF-05212384 (Pfizer) – PI3K/mTOR Inhibitor 6.13 Simtuzumab (Gilead) – Highly Selective for LOXL2 6.14 Talaporfin Sodium (Aptocine, Light Sciences Oncology) – Water-Soluble Drug 6.15 Tivantinib (ARQ 197; ArQule, Daiichi Sankyo) – An Option for EGFR-resistant MET-High mCRC Patients 6.16 Tivozanib (Astellas Pharma/Aveo Pharmaceuticals) – Inhibits VEGF Receptors 6.17 Trametinib (Mekinist, GlaxoSmithKline) – Blocks MEK1 and MEK2 6.18 Veliparib (ABT-888, AbbVie) – An Oral PARP 6.19 RG7221/ RO5520985/Vanucizumab (Roche) – Binds Ang2 and VEGF-A 6.20BKM-120/Buparlisib (Novartis) – Reduces Cellular Levels of Phosphorylated AKT 6.21 BYL-719/Alpelisib (Novartis)
7. Qualitative Analysis of the Colorectal-Cancer Drugs Market 2015-2025 7.1 SWOT Analysis of the Colorectal Cancer Drugs Market 7.1.1 Strengths 7.1.1.1 Rising Incidence of Cancer – Ageing Population 7.1.1.2 Multiple Treatment Options Are Usually Needed 7.1.2 Weaknesses 7.1.2.1 The Challenges of Drug Development 7.1.2.2 The Complex Nature of Cancer 7.1.3 Opportunities in the Cancer Drugs Market 7.1.3.1 The Advancement of Research 7.1.3.2 A Shift Towards Personalisation 7.1.4 Threats Facing the Cancer Drugs Market 7.1.4.1 The Threat of Regulation 7.2.1 Social Factors: The Cost of Living Longer 7.2.2 Technological Developments: Making the Market Move Forward 7.2.3 Economic Pressure: Treatment’s Hefty Price Tag 7.2.4 Political Issues: Governmental Involvement in Treatment
8. Research Interviews from Our Survey – 2015 8.1 Dr. Philip M. Arlen, President and CEO, Precision Biologics, Inc., US 8.1.1 Less Than 1% of Colonoscopies Screening Reveal Cancer 8.1.2 Market Driver - New Drugs with Novel MoA and Favourable Safety Profile 8.1.3 Ensituximab – Developed From a Tumour-Derived Cancer Vaccine 8.1.4 60% of Patients with Colorectal and Pancreatic Cancer Express the Ensituximab Target 8.2 Dr. John Beadle, CEO of PsiOxus Therapeutics, UK 8.2.1 Significant Unmet Need – Effective Treatments for MSI Normal and MSI Low Patients 8.2.2 Checkpoint Inhibitors – Work Well in MSI High Patients 8.2.3 Enadenotucirev Remains Stable in Human Blood 8.2.4 Enadenotucirev – Positioning in the Colorectal Cancer Market?
9. Conclusions of the Study 9.1 Patent Expiries and the Impact of Biosimilars 9.2 The US – Still the Largest National Market 9.3 APAC – Will Show the Fastest Growth 9.4 Colorectal Cancer Drugs R&D Pipeline – Crowded, but How Many Promising Drugs? 9.5 Concluding Remarks
List of Tables Table 1.1 Forecast Regional and National Colorectal Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2015-2025 Table 2.1 Benefits and Limitations of Diagnostic Tests for Colorectal Cancer Table 3.1 Global Colorectal Cancer Drug Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.2 Leading National and Regional Colorectal Cancer Drug Markets: Revenue Forecasts ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2015-2025 Table 3.3 The US Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.4 The Japanese Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.5 The EU Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.6 APAC Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.7 RoW Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.1 Top Colorectal Cancer Drugs: Revenue ($bn) and Market Share (%), 2014 Table 4.2 Top 9 Colorectal Cancer Drugs: Revenue Forecasts ($bn), CAGR (%) and Market Share (%), 2014, 2019, 2025 Table 4.3 Avastin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.4 Roche – Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014 Table 4.5 Erbitux Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.6 Bristol-Myers Squibb – Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014 Table 4.7 Merck KGaA– Revenue ($bn), Change (%) and Share (%), 2014 Table 4.8 Xeloda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.9 Vectibix Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.10 Amgen – Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014 Table 4.11 Eloxatin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.12 Sanofi–Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014 Table 4.13 Zaltrap Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.14 Stivarga Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.15 Bayer– Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014 Table 4.16 TS-1 Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.17 Taiho Pharmaceutical– Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014 Table 4.18 Cyramza Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.19 Eli Lilly – Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014 Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the Colorectal Cancer Drugs Market, 2015 Table 7.2 Social, Technological, Economic and Political Analysis of the Colorectal Cancer Drugs Market, 2015
List of Figures Figure 2.1 Current Standard Treatment Options for Metastatic Colorectal Cancer Figure 3.1 Global Colorectal Cancer Drug Market: Revenue Forecast ($bn), 2015-2025 Figure 3.2 Global Colorectal Cancer Drugs Market: Drivers and Restraints, 2015-2025 Figure 3.3 The Leading National Colorectal Cancer Drugs Markets by Share of Global Market (%), 2014 Figure 3.4 The Leading National Colorectal Cancer Drugs Markets by Share of Global Market (%), 2019 Figure 3.5 The Leading National Colorectal Cancer Drugs Markets by Share of Global Market (%), 2025 Figure 3.6 Developed National Markets: Drivers and Restraints, 2015-2025 Figure 3.7 The US Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025 Figure 3.8 The Japanese Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025 Figure 3.9 The EU Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025 Figure 3.10 APAC Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025 Figure 3.11 Emerging National Markets: Drivers and Restraints, 2015-2025 Figure 3.12 RoW Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025 Figure 4.1 Top 9 Colorectal Cancer Drugs: Market Share (%), 2014 Figure 4.2 Top 9 Colorectal Cancer Drugs: Market Share (%), 2019 Figure 4.3 Top 9 Colorectal-Cancer Drugs: Market Share (%), 2025 Figure 4.4 Avastin Revenue Share by Indication (%), 2014 Figure 4.5 Avastin Revenue Forecast ($bn), 2015-2025 Figure 4.6 Roche’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014 Figure 4.7 Erbitux Revenue Forecast ($bn), 2015-2025 Figure 4.8 Bristol-Myers Squibb’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014 Figure 4.9 Merck KGaA’s Drug by Share of Company Revenue (%), 2014 Figure 4.10 Xeloda Revenue Forecast ($bn), 2015-2025 Figure 4.11 Vectibix Revenue Forecast ($bn), 2015-2025 Figure 4.12 Amgen’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014 Figure 4.13 Eloxatin Revenue Forecast ($bn), 2015-2025 Figure 4.14 Sanofi’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014 Figure 4.15 Zaltrap Revenue Forecast ($bn), 2015-2025 Figure 4.16 Stivarga Revenue Forecast ($bn), 2015-2025 Figure 4.17 Bayer’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014 Figure 4.18 TS-1Revenue Forecast ($bn), 2015-2025 Figure 4.19 Taiho Pharmaceutical Top Selling Cancer Drugs by Share of Company Revenue (%), 2014 Figure 4.20 Cyramza Revenue Forecast ($bn), 2015-2025 Figure 4.21 Eli Lilly’s Top Selling Cancer Drugs by Share of Company Revenue (%), 2014 Figure 9.1 Top 9 Colorectal Cancer Drugs: Revenues ($bn), 2014, 2019, 2025
Abbott AbbVie Amgen Astellas Pharmaceuticals Aveo Pharmaceuticals Bayer BMS Celator Pharmaceuticals Chia Tai Tianqing Pharmaceutical Group CureTech Daiichi Sankyo Eisai Eli Lilly EMEA FDA Genentech Gilead GSK ImClone Immunomedics Jiangsu Hengrui Medicine Light Sciences Oncology Merck KGaA Ministry of Health, Labour and Welfare Japan Morphotek, Inc. NHS NICE Novartis Pfizer Qilu Pharmaceutical Regeneron Roche Sanofi Sillajen Symphogen Syndax Pharmaceuticals Synta Pharmaceuticals Taiho Pharmaceuticals
Download sample pages
Complete the form below to download your free sample pages for Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.
Visiongain Publishes Next Generation Sequencing Market Report 2021-2031
Rising preference for personalised medicine in developed as well as developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase NGS market concentration over the forecast period.
The rising frequency of bacterial and viral diseases coupled with increased focus on immunisation programmes are two main reasons that are expected to boost the global anti-infective vaccines market’s growth in the coming years.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
